Edition:
United States

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

2.30USD
14 Dec 2017
Change (% chg)

$-0.27 (-10.51%)
Prev Close
$2.57
Open
$2.50
Day's High
$2.50
Day's Low
$2.30
Volume
2,214
Avg. Vol
1,153
52-wk High
$7.56
52-wk Low
$2.30

Latest Key Developments (Source: Significant Developments)

Novogen ‍enters into deal to license & assign preclinical assets
Sunday, 12 Nov 2017 05:46pm EST 

Nov 13 (Reuters) - Novogen Ltd ::‍Entered into agreement to license & assign certain preclinical assets to Heaton-Brown Life Sciences​.‍Under terms of deal, co to receive 10 percent of equity in Heaton-Brown Life Sciences.  Full Article

Novogen posts FY loss of $10.7 mln
Tuesday, 29 Aug 2017 06:15pm EDT 

Aug 30 (Reuters) - Novogen Ltd :Novogen reported FY loss of $10.7 million versus loss of $12.1 million last year.FY revenues from ordinary activities down 38.7% to $248.8 million.  Full Article

Novogen Ltd provides update to investors on a review of business operations
Monday, 14 Aug 2017 06:00am EDT 

Aug 14 (Reuters) - Novogen Ltd :Novogen Ltd - provide an update to investors on a review of business operations recently completed by board and management team.Novogen Ltd - directors have offered to reduce their fees, providing additional savings to company.Novogen Ltd - annual cost of board has been reduced by approximately 50%..Novogen - about $1.8 million of annualized savings identified in operating expenses, principally comprising reduction in consultant expenditure, reduction in headcount.  Full Article

Novogen says chairman John O'connor to step down
Wednesday, 7 Jun 2017 08:04pm EDT 

June 8 (Reuters) - Novogen Ltd -:Chairman, john o'connor and non-executive director, ian phillips step down from novogen board.Iain ross appointed chairman.James garner continues as ceo and executive director."Following a review of novogen's fixed cost base, further savings have been identified in general and administrative expense budgets"​."‍expected that these funds will be re-directed to support development of novogen's clinical assets"​.  Full Article

Novogen says CFO Cristyn Humphreys will leave company
Thursday, 9 Mar 2017 05:42pm EST 

Novogen Ltd : Cristyn Humphreys, chief financial officer (CFO) at Novogen will leave Novogen later this month to assume a new role outside industry . Andrew Heaton, CEO of Novogen North America, will leave Novogen .Transition of CFO will be overseen by Kate Hill, formerly a partner at Deloitte, who currently serves as company secretary.  Full Article

Novogen awarded grant for novel drug discovery
Wednesday, 8 Feb 2017 05:37pm EST 

Novogen Ltd - :Novogen awarded grant of up to $3mln for novel drug discovery.  Full Article

Novogen submits IND application for Cantrixil
Thursday, 11 Aug 2016 07:00am EDT 

Novogen Ltd : Novogen submits Investigational New Drug (IND) Application to the U.S. FDA for Cantrixil(TM) in ovarian cancer .Expect to initiate Cantrixil IND study in last quarter of 2016.  Full Article